Eleusis

Eleusis is a life sciences company headquartered in New York that is pioneering the development of psychedelic-derived therapeutics for serious neurological and psychiatric conditions. The company's core focus centers on two primary programs: low-dose LSD as a potential treatment for neuroinflammation associated with Alzheimer's disease, and psilocybin for major depressive disorder. By leveraging the unique pharmacological properties of classical psychedelics, Eleusis aims to develop rigorously tested, clinically validated medicines rather than simply riding the wave of broader psychedelic interest. Their approach integrates deep neuroscience research with formal drug development methodology, positioning the company at the intersection of psychiatry, neurology, and emerging psychedelic medicine.

Eleusis has secured $20 million in Series B funding, reflecting meaningful investor confidence in both its science and commercial potential. The company has conducted early-phase clinical research exploring the safety and immunomodulatory effects of repeated low doses of LSD, generating data that distinguishes it from many peers still in preclinical stages. Their Alzheimer's neuroinflammation program is particularly notable, as it targets an underserved biological mechanism that conventional therapeutics have largely failed to address effectively. These milestones place Eleusis among the more scientifically rigorous players in the rapidly expanding psychedelic medicine sector.

Eleusis represents a meaningful signal for the broader neurotech and mental health technology industry, demonstrating that psychedelic compounds can be developed through conventional pharmaceutical frameworks with institutional credibility. Their work on neuroinflammation in Alzheimer's opens a potentially transformative pathway in a disease area that has seen decades of clinical failure and unmet patient need. As regulatory agencies grow more receptive to psychedelic research following breakthroughs in related fields, companies like Eleusis help establish the scientific and clinical standards that will define this emerging category. Their dual focus on both psychiatric and neurodegenerative indications underscores the broader therapeutic versatility that psychedelic-based medicines may ultimately offer.